MAR 21, 2020 10:28 AM PDT

Modeling Mutations to Beat Drug Resistance

WRITTEN BY: Nouran Amin

Mutations in bacteria or even cancer cells can make them resistant to drug treatments—that means they no longer respond to it and thus continue their harm.

To address this issue, engineers at Penn State have modeled a way of predicting which mutations will occur in people to create an easier path for effective pharmaceuticals.

"Structure-based drug design works very well," said Justin Pritchard, assistant professor of biomedical engineering and holder of the Dorothy Foehr Huck and J. Lloyd Huck Early Career Entrepreneurial Professorship. "It is an amazing ecosystem of technology, but you still have to point it at a set of resistance mutations."

How can this happen? Well researchers know the drugs are developed to the structure of chemicals and their cell targets—however, once a mutation occurs, the cells ‘change’ making them resistant to drugs.

"We need to not just understand the biophysics," said Pritchard. "We also need to understand the evolutionary dynamics."

"If we take out the community aspect of transmission, we can study just the de novo, or 'from nothing,' generation of mutations," said Pritchard.

"We are trying to create a generalized approach to getting the numbers that we use in the models," said Pritchard. "To do this we did not 'fit' the model, but used data obtained from experiments and scaling."

Drug resistance is a critical problem when treating diseases caused by pathogens and cancers. In the study, researchers were curious to know what drives these mutations that lead to resistance.

Learn more about drug resistance:

 

 

"We are trying to create a generalized approach to getting the numbers that we use in the models," said Pritchard. "To do this we did not 'fit' the model, but used data obtained from experiments and scaling."

"We ran the model and it matched clinical data to a degree much better than I ever expected," said Pritchard. "We did this from first principles (basic assumptions)."

Findings of the study was published in Cell Reports.

"We shouldn't always focus on the strongest resistance mutation because there are other evolutionary forces that dictate what happens in the real world," said Pritchard. "Sometimes drug resistance relies on biased random events."

"The data are not quite as strong in the prostate and breast cancer setting," said Pritchard. "In non-small cell lung cancer we didn't see this effect at all."

"If we take out the community aspect of transmission, we can study just the de novo, or 'from nothing,' generation of mutations," said Pritchard.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
FEB 04, 2020
Space & Astronomy
FEB 04, 2020
What Are NASA's 'Great Observatories?'
NASA recently retired its Spitzer Space Telescope, one of four specialized space-based observatories that together made up the American Space Agency’...
FEB 09, 2020
Space & Astronomy
FEB 09, 2020
Here's Why NASA Needs Another Space Station Orbiting the Moon
NASA already has the International Space Station at its disposal, and with that in mind, many have come to question why the American space agency plans to...
FEB 16, 2020
Cancer
FEB 16, 2020
Digital biopsies: coming soon to clinics near you
Research published recently in the Proceedings of the National Academy of Sciences reports the development of a digitized biopsy, one that could be co...
FEB 23, 2020
Space & Astronomy
FEB 23, 2020
NASA Resolves a Minor Hiccup with Voyager 2 Spacecraft's Performance
After spending more than four decades in outer space, NASA’s Voyager 2 spacecraft officially left the heliosphere and entered interstellar space in D...
MAR 22, 2020
Space & Astronomy
MAR 22, 2020
SpaceX to Send Astronauts to the ISS for the First Time in May
NASA’s Commercial Crew Program opened the door to the possibility that American commercial space companies like Boeing and SpaceX would be able to ta...
MAR 30, 2020
Clinical & Molecular DX
MAR 30, 2020
Imaging Platform to Aid in Diagnosis of COVID-19
In the exponential growth of a rapidly spreading infectious disease, healthcare systems become overwhelmed, which can have a cascade of negative effects....
Loading Comments...